CA2991168C - Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use - Google Patents
Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use Download PDFInfo
- Publication number
- CA2991168C CA2991168C CA2991168A CA2991168A CA2991168C CA 2991168 C CA2991168 C CA 2991168C CA 2991168 A CA2991168 A CA 2991168A CA 2991168 A CA2991168 A CA 2991168A CA 2991168 C CA2991168 C CA 2991168C
- Authority
- CA
- Canada
- Prior art keywords
- benzenesulfonamide
- oxoimidazolidin
- amino
- compound
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187636P | 2015-07-01 | 2015-07-01 | |
| US62/187,636 | 2015-07-01 | ||
| PCT/US2016/040736 WO2017004543A1 (en) | 2015-07-01 | 2016-07-01 | Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2991168A1 CA2991168A1 (en) | 2017-01-05 |
| CA2991168C true CA2991168C (en) | 2022-04-26 |
Family
ID=56411955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2991168A Active CA2991168C (en) | 2015-07-01 | 2016-07-01 | Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10562859B2 (https=) |
| EP (1) | EP3317255B1 (https=) |
| JP (1) | JP6795525B2 (https=) |
| KR (1) | KR102637759B1 (https=) |
| CN (1) | CN107922345B (https=) |
| AU (1) | AU2016287587B2 (https=) |
| BR (1) | BR112018000065B1 (https=) |
| CA (1) | CA2991168C (https=) |
| IL (1) | IL256527B (https=) |
| MX (1) | MX387267B (https=) |
| WO (1) | WO2017004543A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2931533T3 (es) * | 2017-04-05 | 2022-12-30 | Harvard College | Compuesto macrocíclico y usos del mismo |
| KR20210000564A (ko) | 2019-06-25 | 2021-01-05 | 공주대학교 산학협력단 | 신규 아만타딘 유도체 화합물 및 이의 용도 |
| CN111233786B (zh) * | 2020-02-04 | 2021-11-26 | 中国人民解放军军事科学院军事医学研究院 | 含五元杂环的苯磺酰胺类化合物及其制备方法和用途 |
| JP7514036B2 (ja) * | 2020-06-02 | 2024-07-10 | イェディテペ・ウニヴェルシテシ | 癌の治療のための炭酸脱水酵素ＩＸ阻害剤としての２－（３－（２－メチル－６－（ｐ－トリル）ピリジン－３－イル）ウレイド）ベンゼンスルホンアミドおよびその誘導体 |
| TR202014185A2 (tr) * | 2020-09-08 | 2022-03-21 | Anadolu Ueniversitesi | BAZI YENİ 4-(2-((5-(SÜBSTİTÜEAMİNO)-1,3,4-TİYADİAZOL-2-İL)TİYO)ASETİL)BENZENSÜLFONAMİD TÜREVLERİ ve SÖZ KONUSU TÜREVLERİN SENTEZİ İÇİN BİR YÖNTEM |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003013655A2 (en) * | 2001-08-10 | 2003-02-20 | Pharmacia Corporation | Carbonic anhydrase inhibitors |
| US20130012485A1 (en) * | 2006-12-22 | 2013-01-10 | Baeschlin Daniel Kaspar | Organic compounds |
| WO2012021963A1 (en) | 2010-07-09 | 2012-02-23 | Metasignal Therapeutics Inc. | Novel sulfonamide compounds for inhibition of metastatic tumor growth |
| WO2013023274A1 (en) * | 2011-08-16 | 2013-02-21 | Universite Laval | Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer |
-
2016
- 2016-07-01 KR KR1020187003119A patent/KR102637759B1/ko active Active
- 2016-07-01 US US15/743,601 patent/US10562859B2/en active Active
- 2016-07-01 JP JP2017568244A patent/JP6795525B2/ja active Active
- 2016-07-01 WO PCT/US2016/040736 patent/WO2017004543A1/en not_active Ceased
- 2016-07-01 CA CA2991168A patent/CA2991168C/en active Active
- 2016-07-01 AU AU2016287587A patent/AU2016287587B2/en active Active
- 2016-07-01 MX MX2018000175A patent/MX387267B/es unknown
- 2016-07-01 BR BR112018000065-5A patent/BR112018000065B1/pt active IP Right Grant
- 2016-07-01 CN CN201680046227.7A patent/CN107922345B/zh active Active
- 2016-07-01 EP EP16738988.1A patent/EP3317255B1/en active Active
-
2017
- 2017-12-24 IL IL256527A patent/IL256527B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US10562859B2 (en) | 2020-02-18 |
| WO2017004543A1 (en) | 2017-01-05 |
| KR102637759B1 (ko) | 2024-02-19 |
| BR112018000065A2 (pt) | 2018-09-11 |
| CN107922345B (zh) | 2021-03-23 |
| US20180201584A1 (en) | 2018-07-19 |
| MX387267B (es) | 2025-03-18 |
| MX2018000175A (es) | 2018-03-26 |
| JP2018519332A (ja) | 2018-07-19 |
| IL256527A (en) | 2018-02-28 |
| HK1248228A1 (en) | 2018-10-12 |
| KR20180023990A (ko) | 2018-03-07 |
| IL256527B (en) | 2021-04-29 |
| JP6795525B2 (ja) | 2020-12-02 |
| CA2991168A1 (en) | 2017-01-05 |
| AU2016287587B2 (en) | 2020-04-30 |
| EP3317255A1 (en) | 2018-05-09 |
| AU2016287587A1 (en) | 2018-01-25 |
| CN107922345A (zh) | 2018-04-17 |
| BR112018000065B1 (pt) | 2023-11-07 |
| EP3317255B1 (en) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3023366T3 (en) | Heteroalkyl dihydroquinoline sulfonamide compounds | |
| EP3820860B1 (en) | Pyridazine compounds for inhibiting nav1.8 | |
| ES2548228T3 (es) | Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio | |
| ES2702951T3 (es) | Inhibidores de quinasas dependientes de ciclina 7 (cdk7) | |
| CA2991168C (en) | Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use | |
| US20230118795A1 (en) | Aryl or heteroaryl pyridone or pyrimidine derivative, preparation method and use thereof | |
| AU2012326361B2 (en) | Substituted biaryl alkyl amides | |
| CN104936944A (zh) | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 | |
| AU2014353006B2 (en) | Quinazoline derivatives as TAM family kinase inhibitors | |
| HK1248228B (en) | Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use | |
| WO2025194094A1 (en) | Small molecule modulators of sirt5 and uses thereof | |
| US9242938B2 (en) | Glycine reuptake inhibitor and use thereof | |
| KR20240149354A (ko) | 헤테로비시클릭 화합물 및 그를 포함하는 약제학적 조성물 | |
| HK1228287B (zh) | 作为tam家族激酶抑制剂的喹唑啉衍生物 | |
| HK40069073B (en) | Compounds, compositions and methods | |
| HK40069073A (en) | Compounds, compositions and methods | |
| HK1228287A1 (en) | Quinazoline derivatives as tam family kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210521 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250627 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250627 |